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ABSTRACT 
Existing detoxification scaffold such as antisera, monoclonal antibodies, small-molecule inhibitors, and molecularly imprinted polymers act by 
targeting the toxins. Special and specific treatments are required for different diseases. Here we show a biomimetic toxin nanosponge that acts 
as a toxin decoy in vivo. The nanosponge consists of a polymeric nanoparticle core surrounded by red blood cell membranes. It absorbs 
membrane-damaging toxins and diverts them away from their cellular targets. Most common toxins in nature, the Pore forming toxins (PFTs), 
distort cells by forming pores in membranes of the cell and alter their permeability. Apart from their roles in bacterial pathogenesis, PFTs are 
commonly engaged in venomous attacks by poisonous animals including sea anemones, scorpions, and snakes. 
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Introduction 
From the 19th century, the field of medicine has flourished at 
an incredible rate. The discovery of antibiotics,anticancer 
drugs, transplant surgeries and various other forms of 
treatment has allowed humans to survive life-threatening 
diseases and deforming diseases like Polio, and many else. Yet, 
there are still diseases that cannot be treated, which has 
allowed traditional medicine to move into the new direction of 
using nanomedicine. [1] 
An ideal drug therapy is the one which has effective 
concentration of drug at the target site for a specified period of 
time in order to prevent or keep to the minimum, general and 
local side effects. To obtain a desirable therapeutic response, 
the proper amount of drug should be transported and 
delivered to the site of action with subsequent controlled 
release. The distribution of drug to other tissues therefore 
seems rather unnecessary, wasteful and a potential cause of 
toxicity. Targeted drug delivery is the delivery of drug to 
receptor, organ or any part of the body to which one wishes to 
deliver the drug exclusively. 
The first nanoparticles were developed by Peter Paul Speiser 
in the year, 1960. The nanoparticles were used for targeted 
drug therapy. This was an impetus for other research 
developing various carrier systems. At the end of the 20th 
century, nanoparticles were modified to transport of DNA 
fragments into cells by using antibodies[2]. Since then there 
has been a efflux of publications in this area. The publications 
have increased from 10 articles in 1990 to 1200 articles in 
2004, illustrating the snowballing interest in nanomedicine [3]. 
Difference between Conventional and Nanomedicine 
Study states that, 40% of Food and Drug administration (FDA) 
approved drugs and 90% of the drugs which are under clinical 
trials are poorly soluble. They have low permeability, rapid 
clearance by the body and are toxic to the cells of the body [4]. 
This study has shown that some conventional drugs do not 
suffice to achieve the desired effect. So, drugs are modified into 
carrier systems to achieve a better pharmaceutical profile. This 
is where nanomedicine comes into play. Water insoluble drugs 
can be encapsulated into the hydrophobic domain of carrier 
systems such as micelles, polymeric nanoparticles and 
liposomes. This enables the drug to be carried by a system that 
has a hydrophilic layer, making drug delivery achievable. Due 
to the size of these encapsulated drug, it provide an 
opportunity for targeting tumours via the enhanced 
permeation and retention effect. The hydrophilic coating 
makes them less predisposed to clearance by the immune 
system, leading to longer time in systemic circulation. These 
carriers can also be modified with ligands or proteins that 
enable therapeutic targeting. Interestingly the application of 
nanocarriers extends to diagnostics as these carriers have 
been modified with imaging contrast agents that selectively 
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target certain cells and can be visualised using techniques such 
as magnetic resonance imaging (MRI) [5]. 
The fields of Nanomedicine have developed ever since the 
emergence of nanoparticles. These nanoparticles come in 
various shapes. However, these systems have been chosen for 
their stealth function as they are coated with particular lipids, 
as found in the human body making detection by immune cells 
difficult. These systems include nanocarriers such as 
liposomes, nanoerythrosomes and micelles [6]. However, they 
may sound like the perfect solution but even these polymeric 
nanoparticles are not above recognition and degradation by 
immune cells [7]. This has led to the development of 
biomimetic strategies. They are characterised by the ability to 
bypass the immune system. Biomimetic nanotherapeutics can 
mimic the cells biological characteristics, as the structure of 
the system is designed in such a way that the particle has a 
polymeric core, coated by a lipid membrane. These particles 
are favored in nanomedicine as they are devised with surface 
features that are specific for targeting cells or tissues[8]. 
Current research has shown that biomimicry include particles 
such as erythrocyte membrane particles with a PLGA core, 
magnetic core, and PLGA cores enveloped by a white blood cell 
membranes[9,10,11] .This area is particularly eyed upon as 
very little research has been conducted on this topic [36]. 
Nanosponge 
Nanosponges is a new concept, made of microscopic particles 
with few nanometers wide cavities in which a large variety of 
substances can be encapsulated[12]. Nanosponges are a novel 
class of hyper-crosslinked polymer based colloidal structures 
consisting of solid nanoparticles with size range similar to that 
of the colloidal dispersed phase and nanosized cavities. Well-
known examples of nanosponges are titanium-based 
nanosponges [13]. 
Nanosponge bead could be of 25μm sized spheres which can 
have up to 2,50,000 pores and an average internal pore 
structure equivalent to 10 feet in length and average pore 
volume of about 1 ml/mg. The drug loading capacity of 
nanosponges mainly depends on the degree of crystallization 
[14]. 
Role in absorption of toxins 
Cell targeting virulence factors like toxins of the bacteria 
illustrate an anitimicrobial approach with potential advantage 
of increasing the collection of bacterial targets, and lowering of 
selective pressure for resistance [15,16]. Among various 
toxins, pore-forming toxins (PFTs) are the most common class 
of bacterial toxins and make up important bacterial virulence 
factors [17]. These toxins distort cells by puncturing them by 
forming pores on their cellular membranes and altering their 
permeability for any bioactivity [18]. However, the majority of 
current toxin targeting platforms, such as antisera [19], 
monoclonal antibodies[20], small-molecule inhibitors [21], 
and molecularly imprinted polymers [22], depends primarily 
on structure-specific epitopic binding and special synthesis is 
required to match specific toxins. As a result, the enormous 
diversity and numbers of PFTs puts up a serious challenge to 
derive an effective detoxification platform against bacterial 
infections. To face this challenge, a unique red blood cell (RBC) 
membrane-coated nanoparticle system has been recently 
developed by wrapping a normal RBC membrane onto 
polymeric nanoparticles (denoted ‘nanosponges’) for wide 
range detoxification applications [23, 24]. The term 
‘nanosponges’ explains the unique capability of the RBC 
membrane-coated nanoparticles for non-specifically ‘soaking 
up’ a broad spectrum of PFTs, just like a sponge soaking up 
water. Unique from existing detoxification approach, these so 
called nanosponges attack the membrane-disrupting 
mechanism which is common to PFTs; thereby offering a toxin 
decoy strategy to absorb various types of their toxins 
irrespective of their molecular structures [25]. 
It has been shown that the blocking of the pore-forming α-
toxin can reduce the severity of Staphylococcus aureus 
infections [26], and just like that PFT-targeted strategies have 
shown therapeutic potential against other pathogens including 
Escherichia coli [27], Listeria monocytogenes [28], Bacillus 
anthracis [29], and Streptococcus pneumoniae [30]. Aside from 
their roles in bacterial pathogenesis, PFTs are commonly 
employed in venomous attacks by animals including sea 
anemones, scorpions, and snakes [31]. The pore forming toxins 
show a diverse molecular structure and over 80 families of 
PFTs have been identified[37]. Despite these differences, there 
is functional similarity among these toxins [36]. 
In toxin Nanosponge, the nano-drug is wrapped with the cell 
membrane of a natural RBC. This structure minister an ideal 
mimicry to absorb a wide range of PFTs no matter what their 
molecular structures is. Simultaneously, the inner polymeric 
core stabilizes the RBC membrane shell to provide prolonged 
systemic circulation which is necessary for absorbing toxins in 
the bloodstream. These nanosponges were prepared by fusing 
RBC membrane vesicles onto poly(lactic-co-glycolic acid) 
(PLGA) nanoparticles through an extrusion approach [32]. 
Under electron microscopy, the resulting nanosponges 
displayed a core-shell structure of approximately 85 nm in 
diameter [33]. Nanosponges can be incorporated into a 
formulated product such as a gel, lotions, cream, ointments, 
liquid or powder [34]. 
Conclusion 
Nanoparticles’ proving advantageous regarding drug targeting, 
delivery, and release along with their additional potential to 
combine diagnosis and therapy, is one of the major tools in 
nanomedicine. The main goals are to improve their stability in 
the biological environment, to mediate the bio-distribution of 
active compounds, improve drug loading, targeting, transport, 
release, and interaction with biological barriers. The 
cytotoxicity of nanoparticles or their degradation products 
remains a major problem, and improvements in 
biocompatibility obviously are a main concern of future 
research [35]. 
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